Michal Ayalon

Michal Ayalon, PhD, is an experienced leader in the biopharmaceutical industry with a robust background in research and development. Currently serving as the Head of In Vitro Pharmacology for Global Biologics at Takeda since December 2023, Michal has previously held positions such as VP Translational Science at xilis and Vice President of Research and Development at Kamada, where responsibilities included R&D strategy and non-clinical activities. Additional experience includes leading R&D at 89bio, overseeing product development at Teva Pharmaceuticals, and managing various roles at Galmed Pharmaceuticals and Immune Pharmaceuticals. Michal holds a PhD in Cell Biology and Immunology and an MSc in Cell/Cellular and Molecular Biology from Tel Aviv University.